§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇸🇦Saudi Arabia	🇺🇸United States
Authority & dossier
Regulatory authority	SFDA	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	None
Reference agencies	FDA, EMA (centralised), MHRA, Health Canada +3	—
Lead pathway (timeline & fees) — Standard Marketing Authorisation (Full Review) · New Drug Application — 505(b)(1)
Pathway name	Standard Marketing Authorisation (Full Review)	New Drug Application — 505(b)(1)
Approval timeline	240–365 days	304–365 days
Application fee	SAR 75,000	USD 4,310,002
Annual renewal	SAR 15,000	USD 416,734
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	A Saudi-resident Pharmacist must be designated as Responsible Person; a Pharmacovigilance Officer is required and must report to the Saudi Pharmacovigilance Centre. Saudisation (Nitaqat) requirements apply to local agent staff.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	4 designations	6 designations
Examples	Priority Review, Orphan Drug Pathway, Conditional Approval +1	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	Variations classified into Major, Minor, and Notification, broadly aligned with EU Type IA/IB/II framework. SFDA also accepts variation worksharing for products approved via the Verification Pathway when the SRA has approved the same change.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Marketing authorisations valid for 5 years; renewal required 6 months before expiry. Renewal includes updated PSUR, sales data, and pharmacovigilance summary.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	Saudi Pharmacovigilance Centre (under SFDA). PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via the National Pharmacovigilance Centre online portal. KSA is a WHO-UMC member.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60–90 days	30–30 days
GCP standard	ICH-GCP	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	Yes	No
HTA body	SFDA Health Technology Assessment (HTA) Unit + Saudi Health Council HTA committee	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

Saudi ArabiaSFDA
United StatesFDA

English submissions

Saudi ArabiaYes
United StatesYes

CTD accepted

Saudi ArabiaYes
United StatesYes

eCTD accepted

Saudi ArabiaYes
United StatesYes

Reliance pathway

Saudi ArabiaAvailable
United StatesNone

Reference agencies

Saudi ArabiaFDA, EMA (centralised), MHRA, Health Canada +3
United States—

Lead pathway (timeline & fees) — Standard Marketing Authorisation (Full Review) · New Drug Application — 505(b)(1)

Pathway name

Saudi ArabiaStandard Marketing Authorisation (Full Review)
United StatesNew Drug Application — 505(b)(1)

Approval timeline

Saudi Arabia240–365 days
United States304–365 days

Application fee

Saudi ArabiaSAR 75,000
United StatesUSD 4,310,002

Annual renewal

Saudi ArabiaSAR 15,000
United StatesUSD 416,734

Local representative

Saudi ArabiaRequired
United StatesNot required

Local manufacturing

Saudi ArabiaNot required
United StatesNot required

GMP inspection

Saudi ArabiaRequired
United StatesRequired

MAH & local presence

Local entity required

Saudi ArabiaYes
United StatesNo

Local responsible person

Saudi ArabiaYes
United StatesYes

RP role

Saudi ArabiaA Saudi-resident Pharmacist must be designated as Responsible Person; a Pharmacovigilance Officer is required and must report to the Saudi Pharmacovigilance Centre. Saudisation (Nitaqat) requirements apply to local agent staff.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Saudi Arabia4 designations
United States6 designations

Examples

Saudi ArabiaPriority Review, Orphan Drug Pathway, Conditional Approval +1
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

Saudi ArabiaVariations classified into Major, Minor, and Notification, broadly aligned with EU Type IA/IB/II framework. SFDA also accepts variation worksharing for products approved via the Verification Pathway when the SRA has approved the same change.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

Saudi ArabiaMarketing authorisations valid for 5 years; renewal required 6 months before expiry. Renewal includes updated PSUR, sales data, and pharmacovigilance summary.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

Saudi ArabiaSaudi Pharmacovigilance Centre (under SFDA). PSURs aligned with ICH E2C(R2). Mandatory ICSR reporting via the National Pharmacovigilance Centre online portal. KSA is a WHO-UMC member.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

Saudi ArabiaAvailable
United StatesAvailable

Compassionate Use

Saudi ArabiaAvailable
United StatesAvailable

Emergency Import

Saudi ArabiaAvailable
United StatesAvailable

Parallel Import

Saudi ArabiaNot permitted
United StatesNot permitted

Clinical trials

CTA approval

Saudi ArabiaRequired
United StatesRequired

Ethics approval

Saudi ArabiaYes
United StatesYes

CTA timeline

Saudi Arabia60–90 days
United States30–30 days

GCP standard

Saudi ArabiaICH-GCP
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

Saudi ArabiaRegulated
United StatesFree pricing

Reference pricing

Saudi ArabiaYes
United StatesNo

HTA required

Saudi ArabiaYes
United StatesNo

HTA body

Saudi ArabiaSFDA Health Technology Assessment (HTA) Unit + Saudi Health Council HTA committee
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding